EMJ Neurology 8 [Supplement 2] . 2020

Measurement of fluid biomarkers of neurodegeneration is an emerging approach offering improved diagnostic accuracy of neuropsychiatric conditions, particularly for atypical presentations. This article reports a case where the diagnosis of delirium with dementia was revised based on biomarker analysis, enabling treatment of a primary mood disorder with resolution of recurrent disabling psychiatric symptoms.

In the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), Alzheimer’s disease (AD [named after the German psychiatrist and neuropathologist, Alois Alzheimer, who first described it]), is considered as a major or mild neuro-cognitive disorder. It is estimated that about 50–70% of total dementia cases are due to this condition, while 10–20% are due to vascular dementia, and it is the fourth leading cause of death in industrialised countries.

People with migraine, and individuals with other neurological conditions, have suffered in multiple aspects during the COVID-19 pandemic. This paper will discuss the factors that impacted the neurology department.

NDM includes a group of rare hereditary neuromuscular disorders caused by mutations in the genes that encode sodium or chloride muscle channels.1 Myotonia is the hallmark symptom of NDM and presents as muscle stiffness, often associated with pain, fatigue, and weakness, which can limit function.